Pharma ‘Making Progress’ On Medicines Access, But Gaps Remain
A new report says that the 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D prioritization and equitable pricing, but not enough is being done to develop new medicines for less profitable diseases or to support flexibilities such as compulsory licensing.
You may also be interested in...
The Medicines Patent Pool has developed a new prioritization framework to identify promising drug candidates for in-licensing, including in the antibiotics area, after its scope was expanded beyond its initial target areas. Later this year it also plans to look at whether its licensing model could be adapted to biologic medicines.
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.
The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.